ADICET BIO INC (ACET) Stock News

NASDAQ:ACET - Nasdaq - US0070021086 - Common Stock - Currency: USD

0.7009 -0.02 (-2.64%)

After market: 0.71 +0.01 (+1.3%)

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

ACET Latest News, Press Relases and Analysis

All

Press Releases

2 days ago - By: Adicet Bio, Inc.

Adicet Bio to Participate in a Fireside Chat at the 45th Annual Canaccord Genuity Growth Conference

14 days ago - By: Adicet Bio, Inc.

Adicet Bio Announces First Systemic Sclerosis (SSc) Patient Dosed in Ongoing Phase 1 Clinical Trial of ADI-001 in Autoimmune Diseases

17 days ago - By: Benzinga - Mentions: XYZ TELO EVO TNFA ...

Why Block Shares Are Trading Higher By 10%; Here Are 20 Stocks Moving Premarket

3 months ago - By: Adicet Bio, Inc.

Adicet Bio to Participate in a Fireside Chat at the 2025 Jefferies Global Healthcare Conference

3 months ago - By: Zacks Investment Research

Adicet Bio (ACET) Upgraded to Buy: Here's What You Should Know

3 months ago - By: Benzinga - Mentions: PLX WORX CTMX CRVS ...

12 Health Care Stocks Moving In Friday's Pre-Market Session

3 months ago - By: Adicet Bio, Inc.

Adicet Bio Reports First Quarter 2025 Financial Results and Provides Business Updates

3 months ago - By: Adicet Bio, Inc.

Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

3 months ago - By: Adicet Bio, Inc.

Adicet Bio to Participate in a Fireside Chat at the Citizens JMP Life Sciences Conference

3 months ago - By: Adicet Bio, Inc.

Adicet Bio Announces Oral Presentation Highlighting Preclinical ADI-270 Data at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting

4 months ago - By: Adicet Bio, Inc.

Adicet Bio Appoints Michael Grissinger to the Board of Directors

4 months ago - By: Adicet Bio, Inc.

Adicet Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

4 months ago - By: Adicet Bio, Inc.

Adicet Bio to Participate in 2025 Canaccord Genuity Horizons in Oncology Virtual Conference

5 months ago - By: Adicet Bio, Inc.

Adicet Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Company Progress

5 months ago - By: Adicet Bio, Inc.

Adicet Announces Poster Presentations Highlighting ADI-270 Data at the Society for Immunotherapy of Cancer (SITC) 2025 Spring Scientific Meeting

5 months ago - By: Adicet Bio, Inc.

Adicet Bio Receives FDA Fast Track Designation for ADI-001 for the Treatment of Systemic Sclerosis (SSc)

6 months ago - By: Adicet Bio, Inc.

Adicet Bio Receives FDA Fast Track Designation for ADI-001 for the Treatment of Refractory Systemic Lupus Erythematosus (SLE) with Extrarenal Involvement

6 months ago - By: Adicet Bio, Inc.

Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

6 months ago - By: Adicet Bio, Inc.

Adicet Bio to Participate in a Fireside Chat at the Guggenheim Securities SMID Cap Biotech Conference

7 months ago - By: Adicet Bio, Inc.

Adicet Bio Provides Corporate Update and Highlights Expected 2025 Milestones

7 months ago - By: Adicet Bio, Inc.

Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

8 months ago - By: Adicet Bio, Inc.

Adicet Bio Announces First Patient Dosed in the Phase 1 Clinical Trial of ADI-270 in Metastatic/Advanced Clear Cell Renal Cell Carcinoma

8 months ago - By: Adicet Bio, Inc.

Adicet Bio Appoints Julie Maltzman, M.D. as Chief Medical Officer

8 months ago - By: Adicet Bio, Inc.

Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

9 months ago - By: Adicet Bio, Inc.

Adicet Opens Enrollment for ADI-270 Phase 1 Clinical Trial in Metastatic/Advanced Clear Cell Renal Cell Carcinoma

9 months ago - By: Adicet Bio, Inc.

Adicet Bio Announces First Lupus Nephritis Patient Dosed in Phase 1 Clinical Trial of ADI-001 in Autoimmune Diseases

9 months ago - By: Adicet Bio, Inc.

Adicet Bio Presents Clinical Biomarker Data for Off-the-Shelf CAR T Cell Therapy in an Oral Session at the American College of Rheumatology (ACR) Convergence 2024

9 months ago - By: Adicet Bio, Inc.

Adicet Reports Third Quarter 2024 Financial Results and Provides Business Updates

9 months ago - By: Adicet Bio, Inc.

Adicet Bio to Present at the American College of Rheumatology (ACR) Convergence 2024

9 months ago - By: Adicet Bio, Inc.

Adicet Bio to Participate in Upcoming Investor Conferences

9 months ago - By: Adicet Bio, Inc.

Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

10 months ago - By: Adicet Bio, Inc.

Adicet Bio Announces FDA Clearance of IND Amendment to Evaluate ADI-001 in Idiopathic Inflammatory Myopathy and Stiff Person Syndrome

10 months ago - By: Adicet Bio, Inc.

Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

10 months ago - By: Adicet Bio, Inc.

Adicet Bio to Present at the American Society of Gene & Cell Therapy’s (ASGCT) 2024 Advancing Gene + Cell Therapies for Cancer Conference

10 months ago - By: Adicet Bio, Inc.

Adicet Opens Enrollment for ADI-001 Phase 1 Clinical Trial in Autoimmune Diseases

a year ago - By: Adicet Bio, Inc.

ADI-001 Clinical Biomarker Data Demonstrate Robust Tissue Trafficking and Complete B Cell Depletion in Secondary Lymphoid Tissue